JaLCDOI 10.18926/AMO/60799
FullText URL 74_5_401.pdf
Author Tsukioki, Takahiro| Shien, Tadahiko| Ohtani, Yusuke| Fujihara, Miwa| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi|
Abstract Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a high frequency of recurrence. However, the prognosis is excellent, with a low mortality rate even when advanced disease is present, although prognostic factors and treatment strategy remain uncertain. Between April 2004 and March 2017, 33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our institution. We retrospectively investigated prognosis and factors including sex, reason for discovery, treatment, pathological factors and treatment progress to clarify the risk factors. All patients underwent curative surgical treatment. Pathologically, lymph node metastasis was identified in 25 patients (75%). Thirteen patients (39%) had bilateral cervical metastasis. In addition, 9 (27%) had more than 10 metastatic lymph nodes. The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI). Five patients (15%) had local recurrences and received surgery. There have been no further recurrences or deaths. However, no factors were determined to significantly predict the recurrence of juvenile DTC. Local recurrent disease was treated with surgery and/or RAI until remission, and survival was excellent in juvenile DTC.
Keywords differentiated thyroid carcinoma juvenile children
Amo Type Original Article
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 401
End Page 406
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106695
FullText URL fulltext.pdf
Author Tsukioki, Takahiro| Shien, Tadahiko| Doihara, Hiroyoshi|
Keywords Breast cancer metastatic stage IV local therapy locoregional therapy surgery survival
Published Date 2020-08
Publication Title Translational Cancer Research
Volume volume9
Issue issue8
Publisher AME Publishing Co.
Start Page 5102
End Page 5107
ISSN 2218-676X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © Translational Cancer Research. All rights reserved.
File Version publisher
DOI 10.21037/tcr.2020.01.60
Web of Science KeyUT 000562138400067
Related Url isVersionOf https://doi.org/10.21037/tcr.2020.01.60
Author Ochi, Kosuke| Suzawa, Ken| Tomida, Shuta| Shien, Kazuhiko| Takano, Jui| Miyauchi, Shunsaku| Takeda, Tatsuaki| Miura, Akihiro| Araki, Kota| Nakata, Kentaro| Yamamoto, Hiromasa| Okazaki, Mikio| Sugimoto, Seiichiro| Shien, Tadahiko| Yamane, Masaomi| Azuma, Kazuo| Okamoto, Yoshiharu| Toyooka, Shinichi|
Keywords Monensin Epithelial-mesenchymal transition Non-small cell lung cancer Drug repositioning Drug resistance
Note This fulltext is available in Jul. 2021.|
Published Date 2020-08-27
Publication Title Biochemical and Biophysical Research Communications
Volume volume529
Issue issue3
Publisher Academic Press
Start Page 760
End Page 765
ISSN 0006-291X
NCID AA00564395
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version Author
PubMed ID 32736704
DOI 10.1016/j.bbrc.2020.06.077
Web of Science KeyUT 000555780500037
Related Url iaVersionOf https://doi.org/10.1016/j.bbrc.2020.06.077
FullText URL CCP_fulltext.pdf
Author Tsukioki, Takahiro| Shien, Tadahiko| Tanaka, Takehiro| Suzuki, Yoko| Kajihara, Yukiko| Hatono, Minami| Kawada, Kengo| Kochi, Mariko| Iwamoto, Takayuki| Ikeda, Hirokuni| Taira, Naruto| Doihara, Hiroyoshi| Toyooka, Shinichi|
Keywords Breast cancer Metformin Preoperative Tils CD8 PD-L1
Published Date 2020-06-12
Publication Title Cancer Chemotherapy and Pharmacology
Volume volume86 volume86
Issue issue1 issue1
Publisher Springer
Start Page 55 55
End Page 63 63
ISSN 0344-5704
NCID AA00598397
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders ©Author(s)
File Version Publisher
PubMed ID 32533334
DOI 10.1007/s00280-020-04092-2
Web of Science KeyUT 000539841500002
Related Url isVersionOf https://doi.org/10.1007/s00280-020-04092-2
FullText URL fulltext.pdf
Author Shien, Tadahiko|
Published Date 2019-03
Publication Title Translational Cancer Research
Volume volume8
Issue issueSuppl. 2
Publisher AME Publishing
Start Page S118
End Page S119
ISSN 2218-676X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version publisher
DOI 10.21037/tcr.2018.11.19
Related Url isVersionOf https://doi.org/10.21037/tcr.2018.11.19
FullText URL fulltext.pdf
Author Shien, Tadahiko| Iwata, Hiroji|
Keywords breast cancer adjuvant neoadjuvant
Note This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.|
Published Date 2020-01-28
Publication Title Japanese Journal of Clinical Oncology
Volume volume50
Issue issue3
Publisher Oxford University Press
Start Page 225
End Page 229
ISSN 0368-2811
NCID AA00690866
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders Copyright © 2020 Oxford University Press
File Version author
PubMed ID 32147701
DOI 10.1093/jjco/hyz213
Web of Science KeyUT 000536439500001
Related Url isVersionOf https://doi.org/10.1093/jjco/hyz213
Author Iwamoto, Takayuki| Fujisawa, Tomomi| Shien, Tadahiko| Araki, Kazuhiro| Sakamaki, Kentaro| Sangai, Takafumi| Kikawa, Yuichiro| Takao, Shintaro| Nishimura, Reiki| Takahashi, Masato| Aihara, Tomohiko| Mukai, Hirofumi| aira, Naruto|
Keywords Metastatic breast cancer Endocrine therapies Estrogen receptor-positive HER2-negative Resistance
Note This fulltext is available in May 2021.|
Published Date 2020-05-11
Publication Title Breast Cancer
Publisher Springer
ISSN 13406868
NCID AA1103354X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 32394413
DOI 10.1007/s12282-020-01095-y
Web of Science KeyUT 000531780600002
Related Url isVersionOf https://doi.org/10.1007/s12282-020-01095-y
FullText URL fulltext.pdf
Author Takeda, Tatsuaki| Yamamoto, Hiromasa| Suzawa, Ken| Tomida, Shuta| Miyauchi, Shunsaku| Araki, Kota| Nakata, Kentaro| Miura, Akihiro| Namba, Kei| Shien, Kazuhiko| Soh, Junichi| Shien, Tadahiko| Kitamura, Yoshihisa| Sendo, Toshiaki| Toyooka, Shinichi|
Keywords breast cancer drug resistance lung cancer neratinib YES1
Published Date 2019-12-19
Publication Title Cancer Science
Volume volume111
Issue issue3
Publisher Wiley
Start Page 849
End Page 856
ISSN 1347-9032
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 The Authors.
File Version publisher
PubMed ID 31856375
DOI 10.1111/cas.14289
Web of Science KeyUT 000507433400001
Related Url isVersionOf https://doi.org/10.1111/cas.14289
FullText URL fulltext.pdf
Author Suzuki, Yoko| Taniguchi, Kohei| Hatono, Minami| Kajiwara, Yukiko| Abe, Yuko| Kawada, Kengo| Tsukioki, Takahiro| Kochi, Mariko| Nishiyama, Keiko| Iwamoto, Takayuki| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Tabata, Masahiro| Yanai, Hiroyuki| Doihara, Hiroyoshi|
Keywords Radiation-induced angiosarcoma Radiotherapy Breast-conserving surgery Breast cancer Paclitaxel therapy Adjuvant therapy of angiosarcoma
Published Date 2020-01-16
Publication Title Surgical Case Reports
Volume volume6
Issue issue1
Publisher SpringerOpen
Start Page 25
ISSN 2198-7793
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s). 2020
File Version publisher
PubMed ID 31950295
DOI 10.1186/s40792-020-0790-7
Web of Science KeyUT 000513920900001
Related Url isVersionOf https://doi.org/10.1186/s40792-020-0790-7
FullText URL OL17_2_2177.pdf
Author Miyoshi, Yuichiro| Shien, Tadahiko| Ogiya, Akiko| Ishida, Naoko| Yamazaki, Kieko| Horii, Rie| Horimoto, Yoshiya| Masuda, Norikazu| Yasojima, Hiroyuki| Inao, Touko| Osako, Tomofumi| Takahashi, Masato| Tomioka, Nobumoto| Wanifuchi‑Endo, Yumi| Hosoda, Mitsuchika| Doihara, Hiroyoshi| Yamashita, Hiroko|
Keywords breast cancer estrogen receptor positive human epidermal growth factor receptor type 2 negative prognosis tumor infiltrating lymphocytes
Published Date 2018-12-19
Publication Title Oncology Letters
Volume volume17
Issue issue2
Publisher Spandidos Publications
Start Page 2177
End Page 2186
ISSN 1792-1074
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version publisher
PubMed ID 30675282
DOI 10.3892/ol.2018.9853
Web of Science KeyUT 000459551800096
Related Url isVersionOf https://doi.org/10.3892/ol.2018.9853
FullText URL fulltext.pdf
Author Takahashi, Yuko| Iwamoto, Takayuki| Suzuki, Yoko| Kajiwara, Yukiko| Hatono, Minami| Tsukioki, Takahiro| Kawada, Kengo| Kochi, Mariko| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| Toyooka, Shinichi|
Keywords Gene expression Hormone receptor positive Residual tumor burden Targeted therapy Triple negative
Published Date 2020-04
Publication Title Clinical Breast Cancer
Volume volume20
Issue issue2
Publisher Elsevier
Start Page 117
End Page 124
ISSN 1526-8209
NCID AA11694891
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version author
PubMed ID 31570267
DOI 10.1016/j.clbc.2019.07.001
Web of Science KeyUT 000529805200021
Related Url isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001
FullText URL BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf
Author Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi|
Keywords BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction
Published Date 2017-03
Publication Title Breast Cancer
Volume volume24
Issue issue2
Publisher Japanese Breast Cancer Society
Start Page 288
End Page 298
ISSN 1340-6868
NCID AA1103354X
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version author
PubMed ID 27179527
DOI 10.1007/s12282-016-0703-6
Web of Science KeyUT 000395524900012
Related Url isVerionOf https://doi.org/10.1007/s12282-016-0703-6
JaLCDOI 10.18926/AMO/54607
FullText URL 70_5_425.pdf
Author Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
Abstract Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age &ge;20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
Keywords breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
Published Date 2016-10
Publication Title Acta Medica Okayama
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 425
End Page 427
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777441
Web of Science KeyUT 000388098700018
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Science KeyUT 000384748600018
JaLCDOI 10.18926/AMO/53907
FullText URL 69_6_333.pdf
Author Ito, Maiko| Shien, Tadahiko| Kaji, Mitsumasa| Mizoo, Taeko| Iwamoto, Takayuki| Nogami, Tomohiro| Motoki, Takayuki| Taira, Naruto| Doihara, Hiroyoshi| Miyoshi, Shinichiro|
Abstract We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
Keywords breast cancer invasive ductal carcinoma 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake values clinicopathological features
Amo Type Original Article
Published Date 2015-12
Publication Title Acta Medica Okayama
Volume volume69
Issue issue6
Publisher Okayama University Medical School
Start Page 333
End Page 338
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26690243
Web of Science KeyUT 000368434500002
Author Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro|
Published Date 2013-12-01
Publication Title BMC Cancer
Volume volume13
Content Type Journal Article
Author Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos|
Published Date 2014-01
Publication Title Breast Cancer Research and Treatment
Volume volume143
Issue issue2
Content Type Journal Article
Author Hayashi, Tatsuro| Asano, Hiroaki| Toyooka, Shinichi| Tsukuda, Kazunori| Soh, Junichi| Shien, Tadahiko| Taira, Naruto| Maki, Yuho| Tanaka, Norimitsu| Doihara, Hiroyoshi| Nasu, Yasutomo| Huh, Nam-ho| Miyoshi, Shinichiro|
Published Date 2012-05
Publication Title Journal of Cancer Research and Clinical Oncology
Volume volume138
Issue issue5
Content Type Journal Article
Title Alternative Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
FullText URL 126_25.pdf
Author Mizoo, Taeko| Shien, Tadahiko| Ito, Maiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
Abstract  Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.  Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.  Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.  Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
Keywords OSNA法(OSNA method) センチネルリンパ節(sentinel lymph node) micrometastases CK-19
Publication Title 岡山医学会雑誌
Published Date 2014-04-01
Volume volume126
Issue issue1
Start Page 25
End Page 30
ISSN 0030-1558
Related Url http://www.okayama-u.ac.jp/user/oma/
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.25
JaLCDOI 10.18926/AMO/50409
FullText URL 67_3_165.pdf
Author Shien, Tadahiko| Kinoshita, Takayuki| Seki, Kunihiko| Yoshida, Miwa| Hojo, Takashi| Shimizu, Chikako| Taira, Naruto| Doihara, Hiroyoshi| Akashi-Tanaka, Sadako| Tsuda, Hitoshi| Fujiwara, Yasuhiro|
Abstract While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to individualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response;pCR) and insensitive patients (clinical no change;cNC and clinical progressinve disease;cPD). In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p=0.045) and histological grade 3 (p=0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC.
Keywords breast cancer neoadjuvant chemotherapy predictors
Amo Type Original Article
Published Date 2013-06
Publication Title Acta Medica Okayama
Volume volume67
Issue issue3
Publisher Okayama University Medical School
Start Page 165
End Page 170
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23804139
Web of Science KeyUT Pretreatment Specimen Predicts